These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23836343)

  • 21. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
    Reddy KJ; Chowdhury S
    Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
    Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786
    [No Abstract]   [Full Text] [Related]  

  • 25. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
    Rupp H
    Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.
    Kim HS; Kim H; Jeong YJ; Yang SJ; Baik SJ; Lee H; Lee SH; Cho JH; Choi IY; Yim HW; Yoon KH
    J Clin Pharm Ther; 2016 Oct; 41(5):508-14. PubMed ID: 27426000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omega-3 fatty acids significantly reduce postprandial triglyceridemia in male smokers: a pilot study.
    Rein P; Saely CH; Aczel S; Patsch B; Drexel H
    Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):e3-4. PubMed ID: 19073364
    [No Abstract]   [Full Text] [Related]  

  • 29. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.
    Serebruany VL; Miller M; Pokov AN; Lynch D; Jensen JK; Hallén J; Atar D
    Cardiology; 2011; 118(3):187-94. PubMed ID: 21701167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omega-3 fatty acids for atypical antipsychotic-associated hypertriglyceridemia.
    Freeman MP; McInerney K; Sosinsky AZ; Kwiatkowski MA; Cohen LS
    Ann Clin Psychiatry; 2015 Aug; 27(3):197-202. PubMed ID: 26247219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Icosapent ethyl for the treatment of hypertriglyceridemia.
    Ballantyne CM; Braeckman RA; Soni PN
    Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia.
    McKeone BJ; Osmundsen K; Brauchi D; Pao Q; Payton-Ross C; Kilinç C; Kummerow FA; Pownall HJ
    J Lipid Res; 1997 Mar; 38(3):429-36. PubMed ID: 9101424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
    Kataoka Y; Uno K; Puri R; Nicholls SJ
    Future Cardiol; 2013 Mar; 9(2):177-86. PubMed ID: 23463969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of omega-3 fatty acid supplementation in primary and secondary prevention of coronary heart disease.
    Weisman D; Motro M; Schwammenthal E; Fisman EZ; Tenenbaum A; Tanne D; Adler Y
    Isr Med Assoc J; 2004 Apr; 6(4):227-32. PubMed ID: 15115262
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention.
    Arca M; Borghi C; Pontremoli R; De Ferrari GM; Colivicchi F; Desideri G; Temporelli PL
    Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):197-205. PubMed ID: 29397253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
    Nordøy A
    Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
    Miller M
    Future Cardiol; 2019 Nov; 15(6):391-394. PubMed ID: 31524535
    [No Abstract]   [Full Text] [Related]  

  • 39. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using omega-3 fatty acids in the practice of clinical lipidology.
    Brown WV; Bays H; Harris W; Miller M
    J Clin Lipidol; 2011; 5(6):424-33. PubMed ID: 22108145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.